Bioventix Announces License Agreement

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

                     Bioventix Announces License Agreement                     

The Company has signed a license agreement with DIAsource ImmunoAssays S.A. of
Belgium ("DIAsource") in relation to certain intellectual property owned by
DIAsource.

In April 2014, the Company announced that it was taking action to oppose
DIAsource's European patent in the field of anti-vitamin D antibodies and their
use in assays (i.e. tests) for vitamin D sufficiency and deficiency.  This
patent is within the scope of the license which DIAsource has granted to the
Company and hence it will cease potentially to restrict Bioventix's business. 
The license features reasonable commercial terms and Bioventix will withdraw
the opposition to the European patent.

Peter Harrison, CEO of Bioventix plc said "We considered the costs of a
potential dispute together with the impact of on-going uncertainty on customers
and shareholders and concluded that a license agreement with DIAsource was the
preferred outcome. With the license agreement now signed, Bioventix's business
is no longer potentially restricted by DIAsource's European patent."

For further information please contact:

Bioventix plc              Chief Executive Officer     Tel: [phone]      
Peter Harrison                                                                 
                                                                               
finnCap Ltd                Corporate Finance           Tel: [phone]      
Geoff Nash/Simon Hicks     Corporate Broking                                   
Steve Norcross                                                                
 

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.